Compare TANH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | RDHL |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.0M |
| IPO Year | 2013 | 2012 |
| Metric | TANH | RDHL |
|---|---|---|
| Price | $20.00 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.1M | 2.5M |
| Earning Date | 05-15-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.57 |
| 52 Week High | $29.89 | $2.79 |
| Indicator | TANH | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 71.20 | 39.85 |
| Support Level | $0.51 | N/A |
| Resistance Level | N/A | $0.85 |
| Average True Range (ATR) | 2.43 | 0.11 |
| MACD | 1.83 | -0.01 |
| Stochastic Oscillator | 63.35 | 0.01 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments: the Consumer Product segment, and the Electric Vehicle (EV) segment.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.